. .

.

  • Yang Wang Hainan Cancer Hospital, Haikou 570312, Hainan Province, China
DOI: https://doi.org/10.5937/jomb0-54181
Ključne reči: .

Sažetak


.

Reference

1. Desai A, Petersm S. Immunotherapy-based combinations in metastatic NSCLC. Cancer Treatment Reviews, 2023;116:102545(1-10).
2. Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Communications, 2022;42(10):937-970.
3. Srivastava S, Mohanty A, Nam A, Singhalm S, Salgian R. Chemokines and NSCLC: emerging role in prognosis, heterogeneity, and therapeutics. Seminars in Cancer Biology, 86(Pt 2):233-246.
4. Benzekry S, Grangeon M, Karlsen M, Alexa M, Bicalho-Frazeto I, Chaleat S, Tomasini P, Barbolosi D, Barlesi F, Greillier L. Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data. Cancers, 2021;13(24):6210(1-12).
5. Liu, H. Association between sleep duration and depression: A Mendelian randomization analysis. Journal of Affective Disorders, 2023;335:152-154.
6. Larkin L. Breast cancer genetics and risk assessment: an overview for the clinician. Climacteric : the Journal of the International Menopause Society, 2023;26(3):229-234.
7. Liu H, Tangm T. Pan-cancer genetic analysis of disulfidptosis-related gene set. Cancer Genetics, 2023;278-279:91-103.
8. Shi Y, Shin DS. Dysregulation of SWI/SNF chromatin remodelers in NSCLC: its influence on cancer therapies including immunotherapy. Biomolecules, 2023;13(6):984(1-20).
9. Tian Y, Xu L, Li X, Li H, Zhao M. SMARCA4: current status and future perspectives in non-small-cell lung cancer. Cancer Letters, 2023;554:216022(1-14).
10. Rotow JK, Lee JK, Madison RW, Oxnard GR, Jänne PA, Schrock AB. Real-world genomic profile of egfr second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2024;19(2):227-239.
11. Grant C, Hagopian G, Nagasaka M. Neoadjuvant therapy in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2023;190:104080(1-8).
12. Zhou S, Shen C, Che G. [Research progress of treatment for NSCLC in young patients]. Zhongguo Fei Ai Za Zhi., 2022;25(12):888-894.
14. Cascone T, Fradette J, Pradhan M, Gibbons DL. Tumor immunology and immunotherapy of non-small-cell lung cancer. Cold Spring Harbor Perspectives in Medicine, 2022;12(5):a037895(1-23).
13. Xu J, Tian L, Qi W, Lv Q, Wang T. Advancements in NSCLC: from pathophysiological insights to targeted treatments. American Journal of Clinical Oncology, 2024;47(6):291-303.
15. Chen ZY, Duan XT, Qiao SM, Zhu XX. Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges. Cancer Med., 2023;12(2):995-1006.
16. Rousseau A, Parisi C, Barlesi F. Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open, 2023;8(2):101184(1-9).
17. Ye D, Jin Y, Weng Y., Cui X, Wang J, Peng M, Song Q. High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC. Scientific Reports, 2023;13(1):16468(1-10).
18. Leung CSK, Van den Eynde BJ. Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC. Cancer Cell, 2022;40(9):903-905.
19. Gong Y, Pang H, Yu Z, Wang X, Li P, Zhang Q. Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity. Annals of Medicine, 2023;55(1):2200034(1-12).
20. Qiao DR, Cheng JY, Yan WQ, Li HJ. PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023;25(8):2373-2383.
Objavljeno
2025/03/05
Broj časopisa
Vol. 44 Br. 3 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2025 Yang Wang

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.